Toll-like receptor 9 (TLR9) recognizes bacterial, viral or cell damage-associated DNA, which initiates innate immune responses. We have previously shown that TLR9 expression is downregulated in several viral induced cancers including HPV16-induced cervical neoplasia. Findings supported that downregulation of TLR9 expression is involved in loss of anti-viral innate immunity allowing an efficient viral replication. Here we investigated the role of TLR9 in altering the growth of transformed epithelial cells. Re-introducing TLR9 under the control of an exogenous promoter in cervical or head and neck cancer patient-derived cells reduced cell proliferation, colony formation and prevented independent growth of cells under soft agar. Neither TLR3, 7, nor the TLR adapter protein MyD88 expression had any effect on cell proliferation, indicating that TLR9 has a unique role in controlling cell growth. The reduction of cell growth was not due to apoptosis or necrosis, yet we observed that cells expressing TLR9 were slower in entering the S-phase of the cell cycle. Microarray-based gene expression profiling analysis highlighted a strong interferon (IFN) signature in TLR9-expressing head and neck cancer cells, with an increase in IFN-type I and IL-29 expression (IFN-type III), yet neither IFN-type I nor IL-29 production was responsible for the block in cell growth. We observed that the protein half-life of p16
INTRODUCTION
Normal tissues carefully control the production and release of growth-promoting signals. These signals will allow entry and progression through the cell development and division cycle, thereby ensuring cell numbers and thus maintenance of normal tissue architecture and function. Cancer cells, by deregulating these signals, permit chronic proliferation. The G1/S checkpoint controls progression of cells through the restriction point into the DNA synthesis S-phase. The p16 INK4a and Kip/Cip family inhibitors control CDK activity and prevent entry into S-phase. p16
INK4a acts as a tumor suppressor through multiple biological functions, including the inhibition of cell cycle progression, 1 the induction of senescence 2 and differentiation, 3 and its involvement in apoptosis 4 and DNA repair. 5 Overexpression of the p16 INK4a gene induced the inhibition of cell proliferation, which has mainly been considered to result from arrest in G1 phase of the cell cycle 6 as well as the lengthening of S-phase. 7 Toll-like receptors (TLRs) are expressed in many hematopoietic cell types, and their role in immune responses has been well documented. 8 However, TLRs are also expressed in nonhematopoietic cells and have an important role in tissue homeostasis as well as cell proliferation. [9] [10] [11] [12] [13] In certain cell types, TLR-dependent signaling results in apoptosis with a mechanism that, in part, depends on the production of type I interferon (IFN). [14] [15] [16] The link between TLR signaling and cell cycle control has been addressed in our previous studies in which we found that flagellin, a TLR5 agonist, can induce cell cycle entry by overcoming p27-induced cell cycle arrest fibroblasts. Our findings also suggested that the differential capacity of TLR3 and TLR4 ligands to induce cell cycle progression is dependent on the ability of these ligands to produce IFN. 14, 17 TLR9 was the first innate immune receptor identified to recognize unmethylated double-stranded DNA CpG motifs expressed in the genome of viruses and bacteria. TLR9 can become activated in response to endogenous double-stranded DNA motifs released as dangerassociated molecular patterns (DAMPs). 18 We and others have observed that oncoviruses such as human papillomavirus 16 and 38 (HPV16 and 38) , Epstein Barr virus, Hepatitis B virus and Merkel cell virus impair the expression and function of the innate immune receptor TLR9 (1, 2, 14, 27) . Furthermore, overexpression of TLR9 (with an exogenous promoter) in human keratinocytes transduced with HPV38E6E7 decreased their ability to grow. 19 Thus, in addition to its role in innate immunity, TLR9 could control events that promote transformation of epithelial cells or cell growth by itself. Here, we describe a role for TLR9 in cell cycle regulation in viral and in non-viral-induced cancers. We observed that as well as in viral induced cancers, we demonstrated in patients with head and neck cancer (that are HPV negative) that TLR9 levels were downregulated. Re-constitution of TLR9 expression in head and neck cancer cells lengthened the S-phase of the cell cycle as well as increase p16
INK4a stability. TLR9 overexpression in head and neck cancer cells also prevented colony formation under soft agar. These data highlight the importance of TLR9 in controlling the events that lead to transformation.
RESULTS

TLR9 expression affects the doubling population of HPV16-transformed cells
We have previously reported the ability of HPV16 viral oncoproteins E6 and E7 (HPV16E6E7) to suppress TLR9 transcription in human primary keratinocytes (HK). To determine the biological significance of HPV16-mediated downregulation of TLR9 transcription, we re-introduced TLR9 into HK and HPV16E6E7 cells by retroviral transduction (Figure 1a) . As previously reported, we observed endogenous TLR9 expression in HK but not in HPV16E6E7-transduced cells 20 ( Figure 1a) . HK, but not HPV16E6E7 cells, were able to produce IL-8 when stimulated with the oligonucleotide CpG 2006, a TLR9 ligand. Yet re-expression of TLR9 restored HPV16E6E7 cells to produce IL-8 in response to CpG 2006 at levels that were comparable to HK (Figure 1b) , indicating that exogenous TLR9 was functional. To determine whether TLR9 expression influenced HK or HPV16E6E7 cell growth we monitored the doubling population over a period of 14 days. HK overexpressing TLR9 failed to grow compared with HK transduced with pbabe alone. Similarly, HPV16E6E7-pbabe-TLR9 cells slowed the growth rate in comparison to HPV16E6E7-pbabe cells from 60 to 20 doublings at day 14 (Figures 1c and d) . To corroborate our data, we analyzed the effect of overexpressing TLR9 (using the pbabe retroviral system) in cells derived from cervical cancer patients (SiHa) positive for HPV16. At 4, 9 and 14 days SiHa cells expressing TLR9 doubled at a slower rate than pbabe alone expressing cells TLR9 slows down the cell cycle P Parroche et al ( Figure 1e ). Taken together, these data show that TLR9 expression prevents cell growth by reducing the doubling population of normal and HPV16-transformed cells.
TLR9 expression is lost in head and neck cancer patients We and others have reported the loss of TLR9 expression in several viral induced cancers. [21] [22] [23] [24] [25] Our next aim was to examine if TLR9 levels were also altered in non-viral induced tumors. Tumor tissue biopsies were taken from 20 patients with head and neck cancer ( − HPV) from the IdiPAZ Biobank, La Pas University Hospital, Spain. Two blind histological analysis was performed by two independent pathologists and classified (see table in Figure 2a ); sections were stained by immunohistochemistry for TLR9 ( Figure 2a) . As a positive control for TLR9 staining we selected skin tissues with a normal histological profile (Figure 2b ). In agreement with the endoplasmic localization of TLR9, basal cells from the normal epidermis showed strong cytoplasmic staining in control tissues (Figures 2a and b) . In head and neck cancer patients weak or no TLR9 staining was observed (Figures 2a  and b) . We also analyzed normal areas in the patient tissue for TLR9 expression and observed that in most cases TLR9 expression was also reduced (data not shown). Furthermore, in cell lines derived from an independent set of head and neck cancer patients. 26 TLR9 mRNA levels were reduced (Figures 2c and d ). We next determined whether restoring TLR9 expression would have an effect on cell growth in head and neck cancer cells. As constant TLR9 exogenous expression in certain experiments TLR9 slows down the cell cycle P Parroche et al caused cell death, we decided to generate an inducible TLR9 expression vector under the control of tetracycline (doxycycline) using the lentiviral vector pLVUT'. 27 TLR9 expression was optimal between 3-5 days post induction with doxycycline in HEK293 cells (data not shown). We chose the head and neck cancer cell lines (HNSCC) 124 and 136 to generate TLR9-expressing clones.
Induction of TLR9 in the 124 cell line led to immediate cell death. We were able to obtain clones for HNSCC 136 in which we observed optimal TLR9 expression 5 days post induction with doxycycline ( Figure 2e and Supplementary Figure 1A ,B). We observed calreticulin (an ER marker in red) and TLR9 (in green) were localized and expressed at similar levels HNSCC 136 cells Figure 1A ,B). We also found that TLR9 overexpression in the HNSCC 136 cell line led to a decrease in cell proliferation compared with the green fluorescent protein (GFP) vector control (Figure 2f ). These results show that TLR9 is also downregulated in non-viral induced HNSCC and its re-expression influences cell growth.
TLR9 expression and not TLR7 or MyD88 affects cell growth TLR9 and TLR7 share the same adapter protein MyD88 in their signaling pathway in order to induce immune gene activation. 28 We therefore tested if MyD88 or TLR7 would also alter cell growth. We observed that neither TLR7 nor MyD88 affected cell growth (Figure 3a) . However, using the same inducible system, we observed that in the presence of doxycycline, MyD88-, TLR9-or TLR7-overexpressing cells that were stimulated with CpG and R848, respectively, were able to induce the transient expression of the nuclear factor-κB reporter gene (Supplementary figure 1C,D) . (Figure 3e ). Therefore, we concluded that TLR9 expression per se inhibited cell growth.
Colony formation and transformation of head and neck cancer cells are altered by TLR9 expression Clonogenic assay or colony-formation assay is an in vitro cell survival assay based on the ability of a single cell to grow into a colony. We observed that overexpressing TLR9 abrogated the ability of 136 cells to form colonies (Figures 4a and b) . Anchorage independent growth of cells in soft agar is one of the hallmarks of cellular transformation and uncontrolled cell growth, with normal cells typically not capable of growth in semisolid matrices. We tested the ability of our 136 head and neck cancer-derived cells to growth under soft agar (Figures 4c and d) . We observed that these cells could grow under soft agar. However, the induction of TLR9 expression led to smaller colony growth under soft agar. Our above findings demonstrate that TLR9 expression alone decreases cancer cell proliferation and colony formation as well as inhibit the events that promote transformation. TLR9 slows down the cell cycle P Parroche et al
TLR9-expressing cells activate an IFN signature
We wanted to determine the molecular processes that might be involved in TLR9 control of cell growth and the events that lead to transformation. We therefore performed microarray-based whole-genome expression profiling analysis on HNSCC 136 cells with inducible TLR9 or GFP control at 36 h post induction with doxycycline ( Figure 5a ). A microarray-based whole-genome expression profiling analysis on HNSCC 136 cells with inducible TLR9 or GFP control at 36 h post induction with doxycycline ( Figure 5a ). Using the BRB-ArrayTools Version: 4.2.1 program, we noted that at 36 h post TLR9 induction, 415 genes were significantly up-or downregulated ranging from 2 to 14.6 absolute fold differences (P-value o0.001; false discovery rate o0.05; data not shown). From Gene ontology annotation implemented in the Database for Annotation, Visualization and Integrated Discovery program (https://david.ncifcrf.gov/), we selected genes that were upregulated and grouped under the 'response to virus' and 'negative effect on cell proliferation' at the 5% false discovery rate level, and used the analysis of variance model to visualize the differentially deregulated genes into a heat map analysis (Figure 5b and Supplementary Figure 2) . We selected some IFN related and others important genes for validation by quantitative PCR (qPCR; Figure 5c ). IFIH1, IL-29, IRF9, IFNB1 and IRF7 were upregulated under the responses to virus classification. IFN genes IL-29, IFNB1 and STAT1 were upregulated and also grouped under negative effect on proliferation. A panel of selected IFN-regulated genes as well as control genes TLR9 and pLS3 (a gene that was downregulated) were validated by qPCR (Figure 5c ). We then postulated that autocrine production of IFN-I or IL-29 by TLR9-expressing HNSCC 136 cells may contribute to the decrease in cell proliferation. We examined if type I (IFNα/β) or type III IFN (IL-29) per se affected cell growth. IFN-β decreased cell growth in 136 cells that expressed TLR9 or GFP ( Figure 6a) ; however, addition of IL-29 did not (Figure 6b) . Moreover, neither IL-29R nor type I IFNR-blocking antibodies altered the inhibitory effect on cell proliferation by TLR9 on 136 cells (Figures 6c-e) . Although TLR9 overexpression does induce an IFN-type signature; our data demonstrate that IFN or IL-29 were not responsible for cell growth inhibition.
TLR9 induces a slowdown of the S-phase in head and neck cancer cells mediated by p16
INK4a
We next wanted to determine cell growth inhibition observed in TLR9-expressing cells also promoted cell death by late apoptotic or necrotic process using PI or 7-AAD inclusion. TLR9-expressing cells did not induce significant cell death (Figure 7a ) as shown by PI or 7-ADD staining. As TLRs have been shown to alter cell proliferation 11, 14, 19 we examined if TLR9 affected the cell cycle. Therefore, the cell cycle length in the head and neck cancer cell line 136 post TLR9 induction was analyzed after cell synchronization using thymidine double blockage. Successive labeling BrdU for 15 min demonstrated that TLR9 induced an accumulation of the G1 phase and lengthening of S-phase (Figure 7b ). Reported by Chien W et al. 29 was the ability of p16 INK4a in human cancer cells to lengthen the S-phase along with the accumulation G1 phase in the cell cycle. Synchronized cells showed that p16
INK4a levels were increased in TLR9-expressing cells (Figures 7c and d) . Recently Yu et al. showed that DNA damage in mammalian cells can signal cell-autonomously to induce endogenous IFN-β in an IRF3-dependent manner. The expression of endogenous IFN-stimulated genes further activated the p53-p21 axis and increased the levels of p16
INK4a concurrent with robustly promoting cell senescence in vitro. 30 Although TLR9 expression did lead to induce IFN stimulatory factors (Figure 5b ) it did not lead to significant changes in p16
INK4a mRNA levels (data not shown) or promoter activity ( Figure 8a ). As p16
INK4a levels were already elevated in TLR9-expressing cells at time point 0, we hypothesized that the protein stability of p16
INK4a may be affected owing to TLR9 expression. To test our hypothesis, 136 cells were transduced with TLR9 or the GFP control and were cultured in a medium containing cycloheximide to inhibit protein synthesis. p16 INK4a half-life was determined by immunoblotting. In TLR9-expressing cells we observed an increase in p16
INK4a stability compared with the GFP control (Figures 8b and c) . These findings demonstrated the mechanism by which TLR9 expression can mediate cell growth slowdown by increasing p16
INK4a stability. Our data highlight a central role for TLR9 in cancer development, therapeutic strategies to reactive its expression should be targeted.
DISCUSSION
The major role of TLRs is to defend the host against pathogens via pathogen-associated molecular pattern recognition, which triggers the innate immune response. We and others share evidences suggesting that loss of TLR9 expression may lead to a poor immune response in viral related cancers. Wu et al., 31 showed that a SNP on the TLR9 promoter at position − 1237, allows increased TLR9 expression that correlated to earlier HBeAg seroconversion. TLR9 slows down the cell cycle P Parroche et al
The − 1237 was also identified by our group as being the site of interaction in which nuclear factor-κBp65/ERα suppressed TLR9 transcription and thus IFN production. 20 Earlier findings from our team revealed that Epstein Barr virus infection of primary B cells led to a decrease in TLR9 mRNA levels, which became increasingly distinct upon immortalization, signifying that the reduction in TLR9 expression may be linked to cellular transformation (19) . Indeed, TLRs also has a role in tissue repair, cell proliferation, apoptosis and angiogenesis. 10, 11, 14, 16, 17 The later activities link TLR signaling to cancer. Although there are evidences that demonstrate specifically that TLR9 is altered in cancer cells, 19, 32, 33 proving their role in carcinogenesis remains changeling. A recent study by Zambirins et al., 13 suggest that TLR9 ligation in pancreatic stellate cells promoted tumorigenesis. Also in a model of hepatocellular carcinoma; hypoxia induced HMGB1 with released mitochondrial DNA lead to the activation of TLR9-mediated tumor growth. 34 On the contrary, TLR9 is downregulated in a several viral and non-induced cancers and that different oncoviruses. 19, [23] [24] [25] 33, [35] [36] [37] Here we have shown that TLR9 expression was reduced in several HNSCC derived from patients. These results were corroborated in tissue biopsies from an independent cohort of head and neck cancer patients. Our new data have showed that the loss of TLR9 expression may also disable its ability to control the cell cycle and events that may control transformation. These results highlight the association of TLR9 in cell cycle control in cancer cells. We show for the first time that TLR9 per se in head and neck cancer cells was able to slowdown the cell cycle during the S-phase. p16
INK4a can act as a tumor suppressor that is implicated in the prevention of cancers, notably melanoma, oropharyngeal squamous cell carcinoma, cervical cancer and esophageal cancer. 29 Chien et al., 29 described that p16INK4a overexpression led to an extended S-phase in cancer cells that contained WTp53. We showed that HNSCC 136 cells, which contained p53WT, which TLR9 expression increased p16
INK4a , which coincided with an extension in the S-phase. The S-phase has an essential role in that any problems with DNA replication trigger a 'checkpoint'-we hypothesize that TLR9 expression leads to signaling events that puts the S-phase on hold until the problem is resolved. It has recently been shown that TLR9 expression is strongly activated via p53 in primary human blood lymphocytes and alveolar macrophages upon exposure to different types of DNA-damaging insults. 27 We speculated that the inhibitory role of TLR9 on cellular proliferation was induced by DAMPs. However, in our experimental setting we were unable to demonstrate that DAMPs released owing to cell death were responsible for TLR9-mediated slowdown in cell growth. Our collaborative work with Pacini et al. 19 also showed that reexpression of TLR9 in HPV38 E6/E7 HFK resulted in a strong accumulation of the cell cycle inhibitors p21 WAF1 and p27 Kip1 and a clear decrease in cellular proliferation. The increase of p21 WAF1 due to TLR9 re-expression was also observed in our model of head and neck cancer (also upregulated in our microarray data: Series record GSE78858). Unlike the study from Pacini et al. 19 we did not observe increased p-p38 or as our previous work has shown p27 Kip1 (data not shown). In our experiments we observed that TLR9-expressing cells increased p16
INK4a protein, which has been shown to positively control the expression of p21(WAF1). 38 We still have to elucidate how TLR9 re-expression allows for p16 INK4a stability. p14ARF has been shown to stabilize p16 INK4a . p14ARF regulates the stability of p16
INK4a protein via REGγ-dependent proteasome degradation. Kobayashi et al., 39 therefore, it would be interesting to determine whether TLR9 re-expression in our model can induce p14ARF. We cannot exclude that certain IFN regulatory transcription factors may also influence the stability of p16 INK4a . 30, 40 In conclusion, in addition to escaping immune recognition, we have shown that the deregulation of TLR9 in viral and non-viral induced cancer may also favor carcinogenesis. Most importantly, our study highlights a novel function of TLR9 in negatively regulated cellular proliferation by increasing the stability of p16 INK4a .
MATERIALS AND METHODS
Expression plasmids
The human TLR9 sequence was previously cloned and described. 41 Human TLR9 and GFP were cloned in the retroviral vector pBabe-puro. 42 The pLVUT is a lentiviral vector expressing GFP downstream from the ubiquitin promoter in a doxycycline-inducible manner. 27 PLVUT' was created from pLVUT to generate a unique EcoRI site downstream of the GFP gene. The EcoRI site at position 6235 was removed by digestion with BstB1. Human TLR9, MyD88 and TLR7 cDNA were cloned into lentiviral pLVUT' vector. Tetracyclin-inducible PLVUT' vector, TLR9, MyD88 and TLR7 were generated by the ISP (Innate Sensors Platform). The pLXSN, HPV16E6E7, pGL3-NF-kB luciferase, pGL3-ELAM luciferase, pGL4-TK and Renilla constructs have been previously described. 20, 36 The p16
INK4a
-luciferase construct was cloned as described by. 43 Cell lines HEK293 and cervical cancer-derived cell lines, SiHa and Caski were obtained from American Type Culture Collection. HNSCC cell lines have been previously described. 44 Cells were maintained in Dulbecco's Modified Eagle Medium supplemented with 10% fetal bovine serum and 10μg/ml ciprofloxacin. Primary human foreskin and embryonic keratinocytes were isolated and grown together with NIH 3T3 feeder cells in FAD medium (Cascade) as previously described, 36 or when in the absence of feeder cells, keratinocytes were grown in EPI-LIFE medium (Cascade) supplemented with growth factors (Cambrex, New Jersey, NJ, USA) and 10 ng/ml human epidermal growth factor (R&D Systems, Lille, France). Cells were cultured at 37°C with 5% CO2. The Caski and HNSCC 136 PLVUT'-GFP and TLR9 were generated after lentiviral transduction and cloned by limited dilution. Ten clones for each cell line positive for WPRE were selected and amplified.
Lentiviral and retroviral infections
Retroviral infections have been previously described. 36 Infected cells were selected with puromycin (1 μg/ml) for 3 days (corresponding to 100% of killing of uninfected cells). Lentiviral particles were produced by the 'plateau technique analyse genetique et vectorologie' (SFR Biosciences UMS3444/US8, Lyon, France). Lentiviral infections were done accordingly to the protocol of the ISP.
RNA extraction, reverse transcriptase-PCR and qPCR RNA was extracted using Nucleospin RNA/protein kit following the manufacturer protocol (Macherey-Nagel, Germany). Reverse transcriptase reaction was performed using 500-1000ng of RNA. For qPCR, complementary DNA were diluted 1/20 for quantitative PCR (qPCR) reactions using Mesa green qPCR Master Mix (Eurogentec, Angers, France). PCR was conducted using the Mx 3000P real-time PCR system (Stratagene, La Jolla, CA, USA). Two sets of PCR assays were conducted for each sample, the TLR9 and β2-microglobulin primers have been described. 35, 45 Amplification specificity was assessed for each sample by melting curve analysis, and the size of the amplicon checked by electrophoresis (data not shown). Relative quantification was performed using standard curve analysis. TLR9 mRNA levels were normalized to β2-microglobulin mRNA levels and are presented as a ratio of gene copy number per 100 copies of β2-microglobulin in arbitrary units.
Functional analysis
Synthetic phosphodiester oligodeoxynucleotides (CpG 2006 and GpC 2006) were synthesized by InvivoGen (Toulouse, France) and used at indicated concentration. IFN-β was used at 100 or 1000 UI/ml (Avonex, Biogen, Nanterre Cedex, France), anti-IL-29, anti-IFNβ (R&D) and anti-IFNAR2 (PBL, New Jersey, NJ, USA). Cells were stimulated overnight and the response was monitored by luciferase assay or enzyme-linked immunosorbent assay. For luciferase assay transient transfection of the reporter plasmid NF-kB, or ELAM luciferase was performed as previously described. 41 Enzyme-linked immunosorbent assays were done in accordance to manufacturer's instructions (R&D system).
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Immunoblot analysis
In brief, harvested cells were lysed in mild lysis buffer containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% Triton X-100, 1 mM DTT, 0.5 mM and complete protease inhibitor (Roche, Meylan, France). Cellular protein content was determined by the Bradford assay (Bio-Rad, Marnes-la-Coquette, France); used for sodium dodecyl sulphate-polyacryl amide gel and immunoblotting onto a polyvinyl difluoride membrane. After incubation with primary antibodies, proteins were detected with secondary peroxidase-conjugated antibodies (Promega, Madison, WI, USA) and ECL. All the primary antibodies for western blotting were from Cell Signaling but the β actin (MP biomedicals, Santa Ana, CA, USA).
Proliferation assay
Doubling population assay and clonogenicity assay were previously described. 46 For MTT assays, cells were plated at 50 000, 100 000 and 150 000 cell/ml in 96-well plate in quadruplicate. After 48 h 10% of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (5 mg/ml) (Sigma-Aldrich, St Louis, CA, USA) was added for 4 h then supernatants were removed and the cells resuspended in dimethyl sulphoxide. The 550nm absorbance was read on a plate reader. For the flow cytometry proliferation analysis, the cells were either stain with PHK 26 fluorescent dye (Sigma-Aldrich, France) or CellTrace violet Cell proliferation kit (Life technologies, France) following manufacturer recommendations. Cell Proliferation Assays: for each cell type, the indicated number of cells/well was seeded into 100 μl of media in 96X microplates (E-Plate). The attachment, spreading and proliferation of the cells were monitored every 30 min using the RT-CES system. Cell proliferation was monitored for 48-72 h, depending on the experiment. Cell-sensor impedance was expressed as an arbitrary unit called the Cell Index. The rate of cell growth was determined by calculating the slope of the line between two given time points.
Flow cytometry analysis
For synchronization experiments, 200 000 cells/ml were plated in a six-well dish. The next day thymidine (2 mM final) was added to the cells, 18 h later the cells were washed three times with PBS and complete medium was added for 9 h. Then thymidine (2 mM final) was added for 18 h. The cells were then washed three times in PBS and complete medium containing BrdU was added. For BrdU cell cycle analysis of non-synchronized cells, 100 000 cells per well were plated. The next day BrdU was added to the plate for 20-30 min. The cells were harvested and washed in PBS then fixed in 70% ethanol overnight at 4°C. The cells were treated with 3N HCl that was neutralized with 0.1 M Na2B4O7 pH 8.5. The cells were then blocked and stained with an anti-BrdU (Biolegend, London, UK) and 7-AAD (Life Technologies). For apoptosis experiment, Apoptosis detection kit I (Becton Dickinson, Le Pont de Claix, France) was used following manufacturer protocol. For TLR9 intracellular staining, one million cells were fixed with 2% paraformaldehyde and permeabilized in PBS containing 0.25% saponin. After blocking the cells were stained with a rat antihuman TLR9 (eBioscience, Paris, France) and with a secondary goat anti-rat Alexa 633. The staining was analyzed on a BD LSRII using the software Diva and FlowJo (Treestar, Ashland, OR, USA).
Histology
IdiPAZ biobank, La Pas University Hospital, Spain. TLR9 staining was performed as previously described 36 and scoring was performed by pathologist Alexandra-Traverse Glehen (Department Laboratoire d'Anatomie et cytologie pathologiques, Hopital Lyon Sud, France).
Soft agar TLR9 or GFP HNSCC 136 cells were plated (150 000 cell/well) in six-well dish and induced in presence or not of doxycycline for 48 h. Cells were then trypsined and counted to include in soft agar assay. Soft agar assay consisting of a 2.5 ml lower layer of 0.75% agar in double-strength Dulbecco's Modified Eagle Medium supplemented with 7.5 g/l NaHCO3 and 10% fetal bovine serum was placed in a six-well plated and permitted to solidify at room temperature. Cells to be tested for colony formation were suspended (22 500 cell/well) in a plating layer of 0.45% agar in double-strength Dulbecco's Modified Eagle Medium containing 10% fetal bovine serum in presence or not of doxycycline. About 100 μl of doublestrength Dulbecco's Modified Eagle Medium containing fetal bovine serum, and doxycycline if indicated, was added to soft agar every 3 days. Pictures were taken 11 days post inclusion.
Isolation of RNA from HNSCC 136 cells HNSCC 136 cells transduced with pLVUT' TLR9 or GFP where plated with the same number of cells and cells were harvested and RNA extracted post as mentioned above post 36 h treatment with doxycyline. RNA concentration and purity were evaluated with the Nanodrop (Thermo Scientific, Illkirch, France). RNA integrity and quantification were characterized by measuring the 28 s/18 s rRNA ratio and RIN (RNA Integrity Number) using the Agilent 2100 bioanalyzer instrument and the RNA 6000 Nano kit. The RIN software classifies the integrity of eukaryotic total RNAs on a scale of 1-10, from most to least degraded.
Microarray-based whole-genome expression profiling and data analysis Genome-wide gene expression profiling analysis was performed on Illumina HumanHT-12 v4 Expression BeadChips, providing a coverage of 424 000 annotated genes (48 783 probes corresponding to 1-3 probes per gene) including well-characterized genes and splice variants. Candidate probe sequences included on the HumanHT-12 v4 Expression BeadChip derive from the National Center for 8 Biotechnology Information Reference Sequence RefSeq (Build 36.2, Rel22) and the UniGene (Build 199) databases. Using the Illumina TotalPrep RNA Amplification Kit (Ambion, Thermofisher, Illkirch, France), 500 ng of extracted RNAs were converted to complementary DNAs and subsequent biotin labeled single-stranded cRNAs. The distribution of homogeneous in vitro transcription products (cRNAs) was checked with the Agilent 2100 bioanalyzer instrument and the RNA 6000 Nano kit. In total, 750 ng of biotin labeled cRNAs of the four (biological triplicates) samples were hybridized overnight to four HumanHT-12 Expression BeadChips. Subsequent steps included washing, streptavadin-Cy3 staining and scanning of the arrays on an Illumina BeadArray Reader. Fluorescence emission by Cy3 was quantitatively detected for downstream analysis. The Illumina Genome Studio V2010.2 was used to obtain the signal values (AVG-Signal), with no normalization and no background subtraction. Data quality controls were performed using internal controls present on the HumanHT-12 beadchip and were visualized as a control summary plot and for each sample as noise-tosignal ratios calculated by P95/P05 signal intensities. All samples had P95/ P05 410, defined as sample quality threshold (data not shown).
Differential expression analysis was performed using BRB-ArrayTools software v4.2 developed by Dr Richard Simon and BRB-ArrayTools Development Team. 47 The raw signal intensities of all samples were log-transformed and quantile normalized with background subtraction with the exclusion of any probe showing excess dispersion (defined by 485% of individual probe values differing from the median by 41.5-fold). Class comparison for Microarray Analysis using the t-test method was performed for identification of differentially expressed probes. Probes with a P-value of o0.001, with a minimum of twofold change and a false discovery rate of o0.05 were considered significantly differentially expressed. The Database for Annotation, Visualization and Integrated Discovery v 6.7 was used for classification of the differentially expressed genes. 48 
Heat map generation
Pre-treatment of data and graphics were carried out with the R statistical langage-Version 3.2.2. In brief, we used the R limma program to perform background correction & quantile normalization. 49 After normalization, the intensities were transformed into log2 and the control probes were removed.
